Close-up on a video camera screen, a woman stares into the lens.

Stay up to date on COVID-19. Learn more

Filter
  • All years
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016

March 10, 2025

Opportunities to get involved with Canada’s health technology assessment agencies and the reimbursement review process

We are excited to share the following opportunities to get involved with Canada’s health technology assessment agencies and the reimbursement review process. Your voice as a person impacted by myeloma is an invaluable contribution to decisions that impact our community. Canada’s Drug Agency (CDA) is currently seeking knowledgeable and experienced individuals to[…]

Learn more

February 7, 2025

“Long wait for cancer drug approvals causing ‘great anguish’ among patients, doctors”

Potentially life-saving treatments delayed by bureaucracy, doctors say In April 2017, Glenn Hussey went to The Ottawa Hospital for a regular checkup to monitor his smouldering multiple myeloma — a precursor to the rare blood plasma cancer multiple myeloma. He’d been going every few months for more than a decade. But this time, he remembers his doctor[…]

Learn more

December 19, 2024

Decisions on CARVYKTI expanded indication

Ciltacabtagene autoleucel (CARVYKTI) has received a notice of compliance (NOC) from Health Canada, approving the treatment for patients with relapsed/refractory multiple myeloma who have received 1-3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and are refractory to lenalidomide.  Canada’s Drug Agency (CDA) conducted a reimbursement review of[…]

Learn more

December 10, 2024

Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement

“Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement” Authors: Guido Lancman, Kevin Song, Darrell White, Tina Crosbie, Ismail Sharif, Marianne Emond, Muhammad Saleem Raza, Martine Elias, Rayan Kaedbey and Michael P. Chu “Here, we have presented a set of recommendations for optimizing the use of T-cell–redirecting therapy in[…]

Learn more

November 22, 2024

Government of Canada establishes a committee of experts to make recommendations on national pharmacare

The Honourable Mark Holland, Minister of Health, announced the establishment of the Committee of Experts which will recommend options on how to operate and finance a national, universal, single-payer pharmacare program in Canada. The Committee will include: Dr. Nav Persaud (Chair); Dr. Stéphane Ahern; Amy Lamb; Dr. Steve Morgan; and, Linda Silas. Over the next year,[…]

Learn more

November 21, 2024

Talquetamab not recommended for reimbursement 

On October 31st the pan-Canadian Oncology Drug Review Expert Review Committee (pERC) of Canada’s Drug Agency (CDA-AMC) decided not to recommend TALVEY (talquetamab) for reimbursement.  The pERC’s draft decision states that due to the limited data available for their review and the nature of its side effects, public drug plans should not fund[…]

Learn more
1 2 3 13